The anti-leukemia drug ponatinib attenuates NLRP3 inflammasome activation in macrophages. (PubMed, Immunobiology) - Sep 6, 2026 - "Ponatinib also reduced IL-1β secretion by microglia, indicating possible NLRP3 inflammasome inhibition in this cell type, but further testing is required. Although ponatinib has previously been demonstrated to drive cardiotoxicity-mediated inflammation, these data suggest that at specific doses, in vitro ponatinib can be non-cytotoxic and effective in attenuating NLRP3 inflammasome activation in macrophages and microglia."
Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Diabetes • Gout • Hematological Malignancies • Inflammation • Inflammatory Arthritis • Leukemia • Metabolic Disorders • Oncology • Rheumatology • CASP1 • IL18 • IL1B • NLRP3
|
|
Abigail H Evered; Daniel C Shippy; Jaidynne N Lash; Sophia F Oliai; Tyler K Ulland
|